Volume 5, Issue 2
Editorialp. 113–115
Giving research participants their voice: assessing comprehension in the informed consent process
Author(s): Judith Lowenburg Forman, Sandra Knowlton-Soho
Editorialp. 117–119
Targeted therapies in oncology: perspectives on trial designs and practical considerations
Author(s): Lindsay A Renfro, Sumithra J Mandrekar
Drug Evaluationp. 121–136
Omalizumab for the treatment of atopic dermatitis
Author(s): Ibon Eguiluz-Gracia, Teresa Robledo-Echarren, Ricardo Suarez-Fernandez, Montserrat Fernandez-Rivas & Silvia Sanchez Ramon
Drug Evaluationp. 137–143
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Author(s): Aida Inbal
Clinical Trail Perspectivep. 145–159
Person-centric clinical trials: defining the N-of-1 clinical trial utilizing a practice-based translational network
Author(s): Frederick A Curro, Dennis A Robbins, Frederick Naftolin, Ashley C Grill, Don Vena & Louis Terracio
Clinical Trail Perspectivep. 161–173
Data fraud in clinical trials
Author(s): Stephen L George, & Marc Buyse
Clinical Trail Methodologyp. 175–188
Personalized medicine: challenges in biomarker-related clinical trial design
Author(s): Pei He
Clinical Trail Outcomesp. 189–204
Antibiotic treatment in exacerbations of chronic obstructive pulmonary disease: recent trial results
Author(s): Kavina Manalan, Taslima Rashid & Aran Singanayagam
Clinical Trail Outcomesp. 205–216
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Author(s): Julie Jaffray & Guy Young
Clinical Trail Outcomesp. 217–228
The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes
Author(s): Assunta Sgambato, Francesca Casaluce, Antonio Rossi, Paolo Maione, Paola Claudia Sacco, Fortunato Ciardiello & Cesare Gridelli
